I. COMMENCED TRADING IN MAY | |||||||||
Company |
Date Filed |
Date |
Shares/Units (M) |
Price |
Shares Out (M) |
Lead, Other Underwriters |
Gross (M) |
Post-Offering Market Cap (M) |
|
| | |||||||||
INITIAL OFFERINGS | |||||||||
There were no initial public offerings conducted in May. | |||||||||
| |||||||||
Total: $0M | |||||||||
Number of IPOs in May: 0 | |||||||||
Average value of May IPOs: $0M | |||||||||
Number of IPOs in 2003: 0 | |||||||||
Total raised in IPOs in 2003: $0M | |||||||||
Average value of IPOs in 2003: $0M | |||||||||
| |||||||||
FOLLOW-ON OFFERINGS | |||||||||
Company (Symbol)# |
Date Filed |
Date Comm. |
Shares/Units (M) |
Price |
Shares Out (M)@ |
Lead, Other Underwriters |
Gross (M) |
Post-Offering Market Cap (M)% |
|
| | |||||||||
BioProgress plc (UK; AIM:BPRG)1 |
5/20/03 |
5/20/03 |
N/A |
N/A |
N/A |
N/A |
£5 (US$8) |
N/A |
|
|
|
|||||||||
ID Biomedical Corp. (Canada; IDBE; TSE:IDB)2 |
5/15/03 |
5/28/03 |
3S |
$8.50 |
35.78 |
CIBC World Markets Canaccord Capital RBC Capital Markets Dlouhy Merchant Group TD Securities Desjardins Securities Wells Fargo Securities |
$25.5 |
$304.13 |
|
Total: $33.5M | |||||||||
Number of follow-on offerings in May: 2 | |||||||||
Average value of May follow-ons: $16.75M | |||||||||
Number of follow-on offerings in 2003: 10 | |||||||||
Total raised in follow-ons in 2003: $627.16M | |||||||||
Average value of follow-ons in 2003: $62.72M | |||||||||
|
| |||||||||
Notes: | |||||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | |||||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | |||||||||
% Market capitalization calculated is based on the offering price; N/A = Not available | |||||||||
AIM = Alternative Investment Market; TSE = Toronto Stock Exchange. | |||||||||
1. BioProgress raised US$8M by listing its stock on London's Alternative Investment Market and delisting it from the OTC Bulletin Board in the U.S. under the symbol “BPRG.“ | |||||||||
2. ID Biomedical raised $25.5M in an offering of 3M shares, which included the underwriters' overallotment option exercised in full. | |||||||||
II. FILED AND PENDING | ||||||
Company (Symbol/ Proposed Symbol)#* |
Date Filed |
Shares/Units (M) |
Price Range |
Shares Out (M)@ |
Lead, Other |
Value (M) |
| | ||||||
INITIAL OFFERINGS | ||||||
ViaCell Inc. |
1/30/02 |
N/A |
N/A |
N/A |
UBS Warburg Banc of America Securities U.S. Bancorp Piper Jaffray |
$115 |
|
|
|||||
FOLLOW-ON OFFERINGS | ||||||
Biomira Inc. |
5/2/02 |
N/A |
N/A |
53.4 |
N/A |
C$150 |
|
|
|||||
BioPure Corp. |
3/6/03 |
N/A |
N/A |
N/A |
N/A |
$20.47 |
|
||||||
Celgene Corp. |
12/21/01 |
N/A |
N/A |
75.6 |
N/A |
$500 |
|
||||||
Cell Genesys Inc. |
12/23/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
||||||
Cell Pathways |
2/7/01 |
N/A |
N/A |
N/A |
N/A |
$25 |
|
||||||
Centrex Inc. |
2/24/03 |
N/A |
N/A |
N/A |
HD Brous & Co. Inc. |
$20 |
|
||||||
Cepheid Inc. |
12/21/01 |
N/A |
N/A |
26.56 |
N/A |
$35 |
|
||||||
Cerus Corp. |
8/13/01 |
N/A |
N/A |
15.7 |
N/A |
$300 |
|
||||||
Cubist |
3/7/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
Dendreon |
1/22/03 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
Exelixis Inc. |
7/30/01 |
N/A |
N/A |
49.2 |
N/A |
$150 |
|
||||||
GenVec Inc. |
12/19/02 |
N/A |
N/A |
N/A |
N/A |
$25 |
|
||||||
Geron Corp. |
1/30/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
||||||
Hemispherx |
1/15/03 |
5S |
$2.16 |
37.6 |
N/A |
$10.8 |
|
||||||
ICOS Corp. |
5/28/03 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
||||||
InSite Vision |
2/2/01 |
N/A |
N/A |
N/A |
Ladenburg Thalmann |
$40 |
|
||||||
Lexicon Genetics |
11/27/02 |
12S |
$3.98 |
N/A |
N/A |
$47.76 |
|
||||||
Lorus |
5/28/03 |
22.8U |
C$1.25 |
N/A |
Loewen, Ondaatje, McCutcheon Dundee Securities Harris Partners Haywood Securities |
C$28.5 |
|
||||||
Neurogen Corp. |
8/16/02 |
N/A |
N/A |
N/A |
N/A |
$75 |
|
||||||
Pharmos Corp. |
2/4/02 |
N/A |
N/A |
56.6 |
N/A |
$25 |
|
||||||
StemCells Inc. |
3/8/02 |
15S |
$2.52 |
25.8 |
N/A |
$37.8 |
|
||||||
Tularik Inc. |
8/14/01 |
N/A |
N/A |
49.2 |
N/A |
$250 |
|
||||||
VaxGen Inc. |
11/7/02 |
N/A |
N/A |
N/A |
N/A |
$150 |
|
| ||||||
Notes: | ||||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||||
* Stock symbols for companies seeking to complete IPOs are proposed. | ||||||
@ This column reflects the shares outstanding following the offering, when disclosed. | ||||||
N/A = Not available, applicable or reported. | ||||||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||||
1. ViaCell filed for a $115M IPO. No further details were disclosed. | ||||||
2. Biomira filed for a C$150M shelf prospectus in Canada. The company raised US$3.7M in a private placement in May. | ||||||
3. BioPure registered to sell up to 10M shares of common | ||||||
stock through a shelf registration. Based on the March 6, 2003, closing stock price of $3.84, the offering would raise $38.4M. Biopure raised $7.3M in private placements conducted in May. | ||||||
4. Celgene filed a universal shelf registration statement to offer and sell common stock, debt securities and convertible debt securities, up to a total value of $500M. In May, Celgene privately placed $400M in convertible notes. | ||||||
5. Cell Genesys filed a shelf registration statement allowing it to issue, from time to time, up to $150M of securities. | ||||||
6. Cell Pathways filed a shelf registration statement for the sale of $25M in common stock. The company privately placed $4.4M in shares in September 2002. | ||||||
7. Centrex plans to raise $20M with HD Brous as its managing underwriter. | ||||||
8. Cepheid filed a shelf registration statement to offer and sell up to $35M of its common stock, preferred stock, debt securities and warrants. Company privately placed $5M in stock in February. | ||||||
9. Cerus filed to sell up to $300M of common stock and debt in a shelf offering. | ||||||
10. Cubist filed a shelf registration statement to sell up to $75M in stock. | ||||||
11. Dendreon filed a shelf registration with the SEC to sell $75M in stock from time to time. | ||||||
12. Exelixis filed a shelf registration statement to sell up to $150M in common stock. | ||||||
13. GenVec filed a $25M shelf registration statement with the SEC. | ||||||
14. Geron filed a prospectus for the sale of up to $150M in debt securities, common or preferred stock and warrants. Geron raised $18.4M in a private placement in April. | ||||||
15. Hemispherx filed to register 5M shares of common stock. The value, $10.8M, is based on the proposed maximum offering price. The company privately placed $5.5M in senior convertible debentures and warrants in March. | ||||||
16. ICOS filed a shelf registration for up to $150M worth of stock, debt securities and convertible debt securities. | ||||||
17. InSite filed a shelf registration statement in February 2001 to sell $40M in stock. | ||||||
18. Lexicon Genetics filed a shelf registration statement with the SEC to sell up to an aggregate of 12M shares of common stock from time to time. The value, $47.76M, is based on the proposed maximum aggregate offering price per share, $3.98. | ||||||
19. Lorus filed a preliminary prospectus in each of the provinces of Canada in connection with a proposed public offering of units. The underwriters have an overallotment option on about 3.4M units. | ||||||
20. Neurogen filed a $75M universal shelf registration statement. | ||||||
21. Pharmos filed a shelf registration statement to sell up to $25M of common stock, preferred stock, debt securities and/or warrants. The company raised $4.3M in a private placement in March. | ||||||
22. StemCells filed with the SEC to sell up to 15M shares to raise a maximum of $37.8M. Further details were not disclosed. The company privately placed $6.5M in shares in May. | ||||||
23. Tularik filed to sell up to $250M in common stock and debt securities. It raised $27.2M in October 2002 with an offering of 4M shares. As of May 2003, $217.8M remains available on the registration statement. | ||||||
24. VaxGen filed a shelf registration statement for $150M in common stock, preferred stock, debt securities and warrants. Further details were not disclosed. It privately placed $5M in stock in May. | ||||||